Confident AstraZeneca gets off to a good start in 2019

26 April 2019
astrazeneca-large

Brisk first quarter trading has given UK drugmaker AstraZeneca (LSE: AZN) a better-than-expected revenue figure of $5.5 billion for the first three months of 2019, up 6% from the same period last year.

Following Generally Accepted Accounting Principles (GAAP), AstraZeneca booked a profit of $1.1 billion, giving an earnings per share (EPS) figure of $0.47, a 75% increase on the first quarter of 2018.

The firm, which announced at the start of the year it had finally  returned to growth, has reaped rewards from a continued focus on oncology and emerging markets, particularly China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical